StockData
BioCryst Pharmaceuticals Inc logo

BioCryst Pharmaceuticals Inc (BCRX) bonds

BCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 9/30
$7.50+0.05 (+0.67%)

Close on Nov 17, 2026Market cap $1.92BP/E –Yield –

Debt

Borrowings on the balance sheet, Jun 30, 2026

Total debt
$395.40M
Long-term debt
Net debt
$240.43M
After $154.97M of cash
Implied interest rate
50.10%
FY2025 interest ÷ average debt
Interest coverage
4.3×
FY2025 operating income ÷ interest

Total debt by fiscal year

Long-term plus current debt, USD

When the debt comes due

Principal repayments of long-term debt by fiscal year, as scheduled at Dec 31, 2019

From the debt maturity table in the annual report (filing). “Later” is everything due after year five.

Notes and loans outstanding

As tagged in BioCryst Pharmaceuticals's 10-Q for the period ended Jun 30, 2026

BioCryst Pharmaceuticals's filings do not break debt down by note

The debt footnote in the annual report has no machine-readable detail for individual notes, so coupons and maturities cannot be listed. The repayment schedule above comes from the same report.

Credit facilities

Revolving credit lines and other committed borrowing capacity

FacilitySizeDrawn
Blackstone$400.00M$400.00M
Blackstone Loan Agreement$400.00M–
Credit Agreement$200.00M$240.45M
Loan Agreement$450.00M–
Term Loan Tranche B$50.00M–
Term Loan Tranche C$50.00M–
Term Loan Tranche D$50.00M–

See a number that looks wrong?